Zongyuan Hong

6PUBLICATIONS
9CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersGene and molecular therapyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 13, 2026
TRIM17 downregulation modulates CRPC progression and enzalutamide resistance by derepressing BCL2 expression via the p53-dependent and p53-independent pathways.

|Jun 01, 2026
APOL3 Orchestrates Metastasis and Enzalutamide Resistance via STAT3-DAB2IP Signaling in Prostate Cancer.

|Feb 06, 2026
Correction: Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.

Junhong Li, Zhe Hong, Junyu Zhang

|Jan 19, 2024
Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.

Junhong Li, Zhe Hong, Junyu Zhang

|Nov 22, 2021
Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.

Licheng Wang, Yicong Yao, Chengdang Xu

|Jul 29, 2021
Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide.

Zhe Hong, Zhendong Xiang, Pan Zhang

Pageof 1

Frequent Collaborators

2 joint publications

Junhong Li

2 joint publications

Bo Dai

2 joint publications

Dingwei Ye

1 joint publications

Quanxin Wang